Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

At the Healthcare Analytics Summit™ 2024 (HAS® 24), Jennifer Doudna, PhD, of the University of California, Berkeley, sat down with Melissa Welch, MD, MPH, President of Welch Perspectives Healthcare ...

New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of ...

The U.S. Patent and Trademark Office issued Caribou Biosciences, a startup co-founded by UC Berkeley researcher Jennifer Doudna, intellectual property rights for developments in CRISPR gene-editing ...

CRISPR co-creator Jennifer Doudna on watching her groundbreaking gene-editing technology help sickle cell patients: “It’s extraordinary.” Jennifer Doudna codeveloped the revolutionary gene-editing ...

The future of CRISPR-based therapies received a windfall this week with the launch of the Danaher-IGI Beacon for CRISPR Cures. The goal of the center is to use CRISPR-based gene editing to permanently ...

Nicole and Kyle Muldoon with their child, KJ, who received a CRISPR gene editing therapy at Children's Hospital of Philadelphia. From the San Francisco Business Times. Months after helping manufacture ...

WASHINGTON, Jan. 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) and the Innovative Genomics Institute (IGI) today launched a collaborative center to develop gene-editing therapies for rare ...